Clinico-pathologic features of non-alcoholic fatty liver disease predicting outcome

Younossi, Z.M.; Matteoni, CA; Gramlich, Terry; Liu, Y; Rybicki, L. A.; McCullough, AJ

doi:10.1016/s0016-5085(98)85561-3

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30,32 The latter two forms have been associated with cirrhosis and liver-related deaths, 32 whereas steatosis alone and steatohepatitis appear to have a more benign clinical course. 32,33 The pathogenesis of NAFL in obesity remains uncertain. It has been proposed that hepatic steatosis results from hyperinsulinemia and inappropriately high amounts of free fatty acids.…”

mentioning

confidence: 99%

“…Moreover, NAFL has the potential to progress to fibrosis/cirrhosis in approximately 25% of cases. 32,[45][46][47] This information, combined with the fact that hepatic steatosis and/or obesity is associated with fibrosis/cirrhosis in alcoholrelated injury [48][49][50][51] and now HCV, 7 makes it important for basic and clinical investigators to explore these associations extensively.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Body composition and hepatic steatosis as precursors for fibrotic liver disease

McCullough

Falck‐Ytter

1999

Hepatology

View full text Add to dashboard Cite

mentioning

confidence: 99%

mentioning

confidence: 99%

Body composition and hepatic steatosis as precursors for fibrotic liver disease

McCullough

Falck‐Ytter

1999

Hepatology

View full text Add to dashboard Cite

“…Ishak et al's [17] modified histological activity index (MHAI) and Metavir [18] scoring system were used to evaluate the inflammatory activity (grade) and fibrosis stage of hepatitis B. Every liver biopsy sample was reviewed according to the NAFLD pathologic protocol [19]. The liver steatosis evaluated in this protocol is divided into four grades: none, 6-32%, 33-66%, and 67-100%.…”

Section: Clinical and Laboratory Evaluationsmentioning

confidence: 99%

Haptoglobin 2-2 Genotype is Related to the Severity of Liver Damage in Hepatitis B Patients with Liver Steatosis

You,

Lu,

Yan

et al. 2023

Discovery Medicine

View full text Add to dashboard Cite

Background: The Haptoglobin (Hp) genotypes have been linked to immune diseases and play a significant role in metabolic diseases. This study aimed to analyze the correlation between Hp gene polymorphism and the severity of hepatitis B accompanied by liver steatosis. Methods: A total of 182 with Hepatitis B and concurrent hepatic steatosis were included in the study. Clinical biochemical indices for each participant were recorded. DNA was extracted from peripheral blood leukocytes for globin genotyping. Of these participants, 128 underwent biopsy from which histological data were collected. Results: Subjects with hepatitis B and hepatic steatosis carrying the Hp 2-2 genotype exhibited elevated alanine transaminase (ALT), c-glutamyl transferase (GGT), and aspartate amino transferase (AST) levels. In contrast, high-density lipoprotein (HDL) levels and the copy number of Hepatitis B Virus (HBV)-DNA were significantly reduced in those with the Hp 2-2 genotype (p < 0.05). Furthermore, individuals processing the Hp 2-2 genotype demonstrated a heightened hepatitis score and advanced fibrosis stage (p < 0.05). Notably, the Hp 2-2 genotype was independently associated with increased inflammation (odds ratio (OR) = 7.059, p < 0.001) and progressive fibrosis (OR = 3.05, p < 0.022). Conclusions: The Hp 2-2 genotype is significantly associated with increased severity in cases of hepatitis B with coexisting hepatic steatosis.

show abstract

Prevalence of Non Alcoholic Steato Hepatitis in Patients With Ischaemic Heart Disease and Hypertension

Sarkar

Ghosh

Kamble

et al. 2022

Global Journal for Research Analysis

View full text Add to dashboard Cite

Non alcoholic steatohepatitis (NASH) which lies in the spectrum of the broader entity Non alcoholic fatty liver disease (NAFLD ) is emerging as a common cause of chronic liver disease.All the patients with NASH have elevated liver enzymes (almost two to three times the normal upper limit) and all of them have sonological abnormality (hepatomegaly and /or fatty inltration). Aim of this study was to measure prevalence of Non Alcoholic Steatohepatitis (NASH) in patients of ischaemic heart disease and hypertension. So, study was conducted in General Medicine Dept until sample size of 75 was reached. All necessary laboratory investigations and clinical parameters were checked. Prevalence of NASH in total study population with history of IHD and or HYPERTENSION is 12%.Conclusion we can say that, prevalence of NON ALCOHOLIC STEATO HEPATITIS (NASH), in patients with ischaemic heart disease and hypertension is low, but there is strong association of metabolic syndrome, with patients having NASH.

show abstract

Clinico-pathologic features of non-alcoholic fatty liver disease predicting outcome

Cited by 3 publications

References 0 publications

Body composition and hepatic steatosis as precursors for fibrotic liver disease

Body composition and hepatic steatosis as precursors for fibrotic liver disease

Haptoglobin 2-2 Genotype is Related to the Severity of Liver Damage in Hepatitis B Patients with Liver Steatosis

Prevalence of Non Alcoholic Steato Hepatitis in Patients With Ischaemic Heart Disease and Hypertension

Contact Info

Product

Resources

About